Abstract：
To evaluate the possible role of systemic inflammation in dry eye disease (DED) via systemic inflammatory marker associations with DED signs and symptoms, and an analysis of a subgroup with Sjogren\'s Syndrome (SS).
Participant serums were analyzed using line immunoassays (LIAs) for the presence of antibodies against 34 systemic inflammatory markers. Using the 2012 American College of Rheumatology definition, the 481 participants were categorized into group 1 (SS; n = 52), group 2 (autoimmune disease not including SS; n = 66), or group 3 (control, i.e. no autoimmune disease; n = 363).
3 markers were positive in ≥10% of participants: Ro52 (19.3%), Scl-70 (15.0%), CN-1A (14.2%). 2 markers were positively associated with symptoms: PM-Scl100 (p = 0.02), Sm (p = 0.009). 5 markers were positively associated with signs: U2SnRNP A\', Ro52, La, DNA, Ro60. SS participants showed significantly higher positivity for 4 markers compared to participants with no autoimmune disease: PL-7 (p = 0.02), Ro52 (p < 0.0001), La (p < 0.0001), Ro60 (p < 0.0001). SS participants showed significantly higher positivity for 3 markers compared to participants with another autoimmune disease: Ro52 (p < 0.0001), La (p = 0.002), Ro60 (p < 0.0001).
This study did not show evidence of significant systemic inflammation in participants with moderate-to-severe DED, based on the markers tested. PM-Scl100 and Sm may be associated with more severe DED symptoms. U2SnRNP A\', Ro52, La, DNA, and Ro60 may be associated with more severe ocular surface disease. Ro52 and PL-7 may be diagnostic markers for SS. Future research evaluating these relationships and their clinical significance is needed.
Participant serums were analyzed using line immunoassays (LIAs) for the presence of antibodies against 34 systemic inflammatory markers. Using the 2012 American College of Rheumatology definition, the 481 participants were categorized into group 1 (SS; n = 52), group 2 (autoimmune disease not including SS; n = 66), or group 3 (control, i.e. no autoimmune disease; n = 363).
3 markers were positive in ≥10% of participants: Ro52 (19.3%), Scl-70 (15.0%), CN-1A (14.2%). 2 markers were positively associated with symptoms: PM-Scl100 (p = 0.02), Sm (p = 0.009). 5 markers were positively associated with signs: U2SnRNP A\', Ro52, La, DNA, Ro60. SS participants showed significantly higher positivity for 4 markers compared to participants with no autoimmune disease: PL-7 (p = 0.02), Ro52 (p < 0.0001), La (p < 0.0001), Ro60 (p < 0.0001). SS participants showed significantly higher positivity for 3 markers compared to participants with another autoimmune disease: Ro52 (p < 0.0001), La (p = 0.002), Ro60 (p < 0.0001).
This study did not show evidence of significant systemic inflammation in participants with moderate-to-severe DED, based on the markers tested. PM-Scl100 and Sm may be associated with more severe DED symptoms. U2SnRNP A\', Ro52, La, DNA, and Ro60 may be associated with more severe ocular surface disease. Ro52 and PL-7 may be diagnostic markers for SS. Future research evaluating these relationships and their clinical significance is needed.
摘要：
■通过全身性炎症标志物与干眼病（DED）体征和症状的关联，评估全身性炎症在DED中的可能作用，并对干燥综合征（SS）亚组进行了分析。
使用线免疫测定法(LIAs)分析针对34种全身性炎症标志物的抗体的存在。使用2012年美国风湿病学会的定义，481名参与者被归类为第1组(SS；n=52)，第2组（不包括SS的自身免疫性疾病；n=66），或第3组(对照，即无自身免疫性疾病；n=363）。
■在≥10％的参与者中有3个标记为阳性：Ro52（19.3％），Scl-70（15.0%），CN-1A(14.2%)。2个标记与症状呈正相关：PM-Scl100（p=0.02），Sm(p=0.009)。5个标记与体征呈正相关：U2SnRNPA\'，Ro52,La,DNA,Ro60与无自身免疫性疾病的参与者相比，SS参与者对4种标志物的阳性显著更高：PL-7（p=0.02），Ro52（p<0.0001），La(p<0.0001),Ro60（p<0.0001）。与另一种自身免疫性疾病的参与者相比，SS参与者对3种标志物的阳性显着提高：Ro52（p<0.0001），La(p=0.002),Ro60（p<0.0001）。
■本研究未显示中度至重度DED患者存在明显全身性炎症的证据，基于测试的标记。PM-Scl100和Sm可能与更严重的DED症状相关。U2SnRNPA\',Ro52,La,DNA,Ro60可能与更严重的眼表疾病相关。Ro52和PL-7可以是SS的诊断标记。需要进一步研究评估这些关系及其临床意义。
使用线免疫测定法(LIAs)分析针对34种全身性炎症标志物的抗体的存在。使用2012年美国风湿病学会的定义，481名参与者被归类为第1组(SS；n=52)，第2组（不包括SS的自身免疫性疾病；n=66），或第3组(对照，即无自身免疫性疾病；n=363）。
■在≥10％的参与者中有3个标记为阳性：Ro52（19.3％），Scl-70（15.0%），CN-1A(14.2%)。2个标记与症状呈正相关：PM-Scl100（p=0.02），Sm(p=0.009)。5个标记与体征呈正相关：U2SnRNPA\'，Ro52,La,DNA,Ro60与无自身免疫性疾病的参与者相比，SS参与者对4种标志物的阳性显著更高：PL-7（p=0.02），Ro52（p<0.0001），La(p<0.0001),Ro60（p<0.0001）。与另一种自身免疫性疾病的参与者相比，SS参与者对3种标志物的阳性显着提高：Ro52（p<0.0001），La(p=0.002),Ro60（p<0.0001）。
■本研究未显示中度至重度DED患者存在明显全身性炎症的证据，基于测试的标记。PM-Scl100和Sm可能与更严重的DED症状相关。U2SnRNPA\',Ro52,La,DNA,Ro60可能与更严重的眼表疾病相关。Ro52和PL-7可以是SS的诊断标记。需要进一步研究评估这些关系及其临床意义。
